Apellis Pharmaceuticals, Inc.
US ˙ NasdaqGS ˙ US03753U1060

Introduktion

Denne side giver en omfattende analyse af den kendte insiderhandelshistorie for Pascal Deschatelets. Insidere er embedsmænd, direktører eller betydelige investorer i en virksomhed. Det er ulovligt for insidere at foretage handler i deres virksomheder baseret på specifik, ikke-offentlig information. Dette betyder ikke, at det er ulovligt for dem at handle i deres egne virksomheder. De skal dog rapportere alle handler til SEC via en formular 4. På trods af disse begrænsninger tyder akademisk forskning på, at insidere - generelt - har en tendens til at klare sig bedre end markedet i deres egne virksomheder.

Gennemsnitlig handelsrentabilitet

Den gennemsnitlige handelsrentabilitet er det gennemsnitlige afkast af alle køb på det åbne marked foretaget af insideren i de sidste tre år. For at beregne dette undersøger vi ethvert åbent marked, uplanlagte køb foretaget af insideren, eksklusive alle handler, der var markeret som en del af en 10b5-1-handelsplan. Vi beregner derefter den gennemsnitlige præstation for disse handler over 3, 6 og 12 måneder, idet vi tager et gennemsnit af hver af disse varigheder for at generere en endelig præstationsmåling for hver handel. Endelig tager vi et gennemsnit af alle præstationsmålingerne for at beregne en præstationsmåling for insideren. Denne liste inkluderer kun insidere, der har foretaget mindst tre handler i de sidste to år.

Hvis denne insiderhandelsrentabilitet er "N/A", så har insideren enten ikke foretaget nogen køb på det åbne marked i de sidste tre år, eller de handler, de har foretaget, er for nye til at beregne en pålidelig præstationsmåling.

Opdateringsfrekvens: Dagligt

Se listen over de mest profitable insiderhandlere.

Virksomheder med rapporterede insider-stillinger

SEC-registreringen viser, at Pascal Deschatelets har rapporteret besiddelser eller handler i følgende virksomheder:

Sikkerhed Titel Senest indberettede beholdninger
US:APLS / Apellis Pharmaceuticals, Inc. Chief Scientific Officer 1.160.496
Sådan fortolkes diagrammerne

Følgende diagrammer viser aktieudviklingen for værdipapirer efter hver åben-marked, ikke-planlagt handel foretaget af Pascal Deschatelets. Ikke-planlagt handel er handler, der ikke blev foretaget som en del af en 10b5-1-handelsplan. Aktieudviklingen er kortlagt som den kumulative procentvise ændring i aktiekursen. For eksempel, hvis en insiderhandel blev foretaget den 1. januar 2019, vil diagrammet vise den daglige procentvise ændring af værdipapiret til i dag. Hvis aktiekursen skulle gå fra $10 til $15 i løbet af denne tid, ville den kumulative procentvise ændring i aktiekursen være 50%. En prisændring fra 10 USD til 20 USD ville være 100 %, og en ændring i prisen på 10 USD til 5 USD ville være -50 %.

I sidste ende forsøger vi at bestemme, hvor tæt insiderens handler korrelerer med merafkast (positive eller negative) i aktiekursen for at se, om insideren timing deres handler til at drage fordel af insiderinformation. Overvej situationen, hvor en insider gjorde dette. I denne situation ville vi forvente enten (a) positive afkast efter køb eller (b) negative afkast efter salg. I tilfælde af (a) vil KØB-diagrammet vise en række opadskrånende kurver, der indikerer positive afkast efter hver købstransaktion. I tilfælde af (b) vil SALE-diagrammet vise en række nedadgående kurver, der indikerer negative afkast efter hver salgstransaktion.

Dette alene er dog ikke nok til at drage konklusioner. Hvis for eksempel aktiekursen i selskabet var i en ikke-cyklisk stigning over mange år, så ville vi forvente, at alle efterkøbsgrundene var opadgående. Ligeledes ville ikke-cykliske fald over mange år resultere i nedadgående post-trade plots. Ingen af disse diagrammer tyder på insiderhandel.

Den stærkeste indikator ville være en situation, hvor aktiekursen var ekstremt cyklisk, og der var både positive signaler i KØB-diagrammet og negative plots på SALG-diagrammet. Denne situation ville i høj grad tyde på en insider, der havde timing af handler til deres økonomiske fordel.

Insiderkøb APLS / Apellis Pharmaceuticals, Inc. – kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i APLS / Apellis Pharmaceuticals, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Maks
Pris kl
Maks
Maks
Fortjeneste ($)
Maks. afkast (%)
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

APLS / Apellis Pharmaceuticals, Inc. Insider Trades
Insidersalg APLS / Apellis Pharmaceuticals, Inc. – kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i APLS / Apellis Pharmaceuticals, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Min
Pris kl
Min
Max tab
Undgået ($)
Max tab
Undgået (%)
2025-01-29 APLS Deschatelets Pascal 826 29,5236 826 29,5236 24.386 106 16.3600 -10.873 -44,59
2025-01-22 APLS Deschatelets Pascal 3.948 30,4255 3.948 30,4255 120.120
2025-01-17 APLS Deschatelets Pascal 750 29,9582 750 29,9582 22.469
2025-01-13 APLS Deschatelets Pascal 2.288 28,7021 2.288 28,7021 65.670
2024-02-12 APLS Deschatelets Pascal 1.148 67,7669 1.148 67,7669 77.796
2024-01-29 APLS Deschatelets Pascal 874 64,1382 874 64,1382 56.057
2024-01-22 APLS Deschatelets Pascal 3.913 64,9960 3.913 64,9960 254.329
2024-01-16 APLS Deschatelets Pascal 1.632 66,8086 1.632 66,8086 109.032
2023-09-08 APLS Deschatelets Pascal 12.000 42,8700 12.000 42,8700 514.440
2021-03-10 APLS Deschatelets Pascal 6.250 50,7400 6.250 50,7400 317.125
2020-02-13 APLS Deschatelets Pascal 55.398 40,9790 55.398 40,9790 2.270.155
2020-02-12 APLS Deschatelets Pascal 52.075 42,8030 52.075 42,8030 2.228.966

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

APLS / Apellis Pharmaceuticals, Inc. Insider Trades
Insiderhandelshistorie

Denne tabel viser den komplette liste over insiderhandler foretaget af Pascal Deschatelets som oplyst til Securities Exchange Commission (SEC).

Fil dato Transdato Form Ticker Sikkerhed Kode 10b5-1 Aktier Resterende aktier Procent
Lave om
Del
Pris
Tran
Værdi
Tilbage
Værdi
2025-05-22 2025-05-21 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
M - Exercise 12.780 1.160.496 1,11 3,76 48.053 4.363.465
2025-01-30 2025-01-29 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale -826 1.147.716 -0,07 29,52 -24.386 33.884.708
2025-01-23 2025-01-22 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale -3.948 1.148.542 -0,34 30,43 -120.120 34.944.965
2025-01-21 2025-01-21 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
A - Award 15.045 1.152.490 1,32
2025-01-21 2025-01-17 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale -750 1.137.445 -0,07 29,96 -22.469 34.075.805
2025-01-14 2025-01-13 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale -2.288 1.138.195 -0,20 28,70 -65.670 32.668.587
2024-05-21 2024-05-20 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
M - Exercise 24.500 1.140.483 2,20 3,76 92.120 4.288.216
2024-05-09 2024-05-08 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale X -100 1.115.983 -0,01 44,02 -4.402 49.131.152
2024-05-09 2024-05-08 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale X -22.472 1.116.083 -1,97 42,85 -962.903 47.823.040
2024-05-09 2024-05-08 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale X -56.335 1.138.555 -4,71 42,15 -2.374.543 47.990.549
2024-05-09 2024-05-08 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
M - Exercise X 78.907 1.194.890 7,07 4,31 340.089 5.149.976
2024-04-09 2024-04-08 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale X -4.728 1.115.983 -0,42 54,92 -259.639 61.284.430
2024-04-09 2024-04-08 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale X -64.379 1.120.711 -5,43 54,12 -3.483.966 60.648.957
2024-04-09 2024-04-08 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
M - Exercise X 69.107 1.185.090 6,19 3,76 259.842 4.455.938
2024-03-11 2024-03-08 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale X -100 1.115.983 -0,01 63,35 -6.335 70.697.523
2024-03-11 2024-03-08 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale X -26.257 1.116.083 -2,30 62,69 -1.646.041 69.966.797
2024-03-11 2024-03-08 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale X -42.750 1.142.340 -3,61 61,88 -2.645.173 70.682.744
2024-03-11 2024-03-08 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
M - Exercise X 69.107 1.185.090 6,19 3,67 253.623 4.349.280
2024-02-13 2024-02-12 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale -1.148 1.115.983 -0,10 67,77 -77.796 75.626.708
2024-01-31 2024-01-29 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale -874 1.117.131 -0,08 64,14 -56.057 71.650.772
2024-01-23 2024-01-22 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale -3.913 1.118.005 -0,35 65,00 -254.329 72.665.853
2024-01-17 2024-01-16 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale -1.632 1.121.918 -0,15 66,81 -109.032 74.953.771
2024-01-17 2024-01-16 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
A - Award 6.743 1.123.550 0,60
2023-11-15 2023-11-14 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
M - Exercise 45.000 1.116.807 4,20 3,76 169.200 4.199.194
2023-11-09 2023-11-08 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale X -12.000 1.071.807 -1,11 47,27 -567.240 50.664.317
2023-11-09 2023-11-08 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
M - Exercise X 17.494 1.083.807 1,64 2,67 46.709 2.893.765
2023-10-10 2023-10-09 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale X -12.000 1.066.313 -1,11 40,38 -484.560 43.057.719
2023-10-10 2023-10-09 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
M - Exercise X 18.500 1.078.313 1,75 2,67 49.395 2.879.096
2023-09-11 2023-09-08 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale -12.000 1.059.813 -1,12 42,87 -514.440 45.434.183
2023-09-11 2023-09-08 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
M - Exercise X 18.500 1.071.813 1,76 2,67 49.395 2.861.741
2023-08-09 2023-08-08 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale X -12.000 1.053.313 -1,13 23,66 -283.920 24.921.386
2023-08-09 2023-08-08 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
M - Exercise X 18.500 1.065.313 1,77 2,67 49.395 2.844.386
2023-07-11 2023-07-10 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale X -12.000 1.046.813 -1,13 84,55 -1.014.600 88.508.039
2023-07-11 2023-07-10 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
M - Exercise X 18.500 1.058.813 1,78 2,67 49.395 2.827.031
2023-06-09 2023-06-08 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale X -12.000 1.040.313 -1,14 91,35 -1.096.200 95.032.593
2023-06-09 2023-06-08 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
M - Exercise X 18.500 1.052.313 1,79 2,67 49.395 2.809.676
2023-05-09 2023-05-08 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale X -12.000 1.033.813 -1,15 92,39 -1.108.680 95.513.983
2023-05-09 2023-05-08 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
M - Exercise X 18.500 1.045.813 1,80 2,67 49.395 2.792.321
2023-04-11 2023-04-10 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale X -12.000 1.027.313 -1,15 78,21 -938.520 80.346.150
2023-04-11 2023-04-10 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
M - Exercise X 18.500 1.039.313 1,81 2,67 49.395 2.774.966
2023-03-10 2023-03-08 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale X -12.000 1.020.813 -1,16 63,79 -765.480 65.117.661
2023-03-10 2023-03-08 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
M - Exercise X 18.500 1.032.813 1,82 2,67 49.395 2.757.611
2023-02-22 2023-02-21 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
F - Taxes -1.195 1.014.313 -0,12 58,50 -69.908 59.337.310
2023-02-22 2023-02-21 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
A - Award 9.886 1.015.508 0,98
2023-02-14 2023-02-10 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
F - Taxes -1.134 1.005.622 -0,11 51,21 -58.072 51.497.903
2023-02-10 2023-02-08 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale X -12.000 1.006.756 -1,18 54,45 -653.400 54.817.864
2023-02-10 2023-02-08 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
M - Exercise X 18.500 1.018.756 1,85 2,67 49.395 2.720.079
2023-01-30 2023-01-27 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
F - Taxes -832 1.000.256 -0,08 52,77 -43.905 52.783.509
2023-01-24 2023-01-20 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
F - Taxes -2.326 1.001.088 -0,23 52,05 -121.068 52.106.630
2023-01-17 2023-01-12 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
A - Award 19.634 1.003.414 2,00
2023-01-10 2023-01-09 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale X -12.000 983.780 -1,21 46,08 -552.960 45.332.582
2023-01-10 2023-01-09 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
M - Exercise X 18.500 995.780 1,89 2,67 49.395 2.658.733
2022-12-30 2022-12-29 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
M - Exercise 7.000 977.280 0,72 3,67 25.690 3.586.618
2022-12-12 2022-12-08 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale X -12.000 970.280 -1,22 47,50 -570.000 46.088.300
2022-12-12 2022-12-08 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
M - Exercise X 18.500 982.280 1,92 2,67 49.395 2.622.688
2022-11-10 2022-11-08 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale X -12.000 963.780 -1,23 46,47 -557.640 44.786.857
2022-11-10 2022-11-08 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
M - Exercise X 18.500 975.780 1,93 2,67 49.395 2.605.333
2022-10-11 2022-10-10 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale X -12.000 957.280 -1,24 57,50 -690.000 55.043.600
2022-10-11 2022-10-10 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
M - Exercise X 18.500 969.280 1,95 2,67 49.395 2.587.978
2022-09-12 2022-09-08 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale X -12.000 950.780 -1,25 63,98 -767.760 60.830.904
2022-09-12 2022-09-08 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
M - Exercise X 18.500 962.780 1,96 2,67 49.395 2.570.623
2022-08-09 2022-08-08 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale X -12.000 944.280 -1,25 62,50 -750.000 59.017.500
2022-08-09 2022-08-08 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
M - Exercise X 18.500 956.280 1,97 2,67 49.395 2.553.268
2022-07-12 2022-07-08 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale X -12.000 937.780 -1,26 47,95 -575.400 44.966.551
2022-07-12 2022-07-08 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
M - Exercise X 6.500 949.780 0,69 2,67 17.355 2.535.913
2022-07-12 2022-07-08 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
M - Exercise X 12.000 943.280 1,29 2,67 32.040 2.518.558
2022-06-22 2022-06-17 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
M - Exercise X 33.005 931.280 3,67 2,67 88.123 2.486.518
2022-06-09 2022-06-08 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
M - Exercise X 6.500 898.275 0,73 2,67 17.355 2.398.394
2022-06-09 2022-06-08 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale X -12.000 891.775 -1,33 44,09 -529.080 39.318.360
2022-06-09 2022-06-08 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
M - Exercise X 12.000 903.775 1,35 2,67 32.040 2.413.079
2022-05-02 2022-04-29 4 APLS Apellis Pharmaceuticals, Inc.
Stock Option (Right to Buy)
M - Exercise X -4.000 364.999 -1,08
2022-05-02 2022-04-29 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale X -4.000 891.775 -0,45 44,43 -177.720 39.621.563
2022-05-02 2022-04-29 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
M - Exercise X 4.000 895.775 0,45 2,67 10.680 2.391.719
2022-05-02 2022-04-21 4 APLS Apellis Pharmaceuticals, Inc.
Stock Option (Right to Buy)
J - Other -11.250 0 -100,00
2022-05-02 2022-04-21 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
J - Other -1.875 891.775 -0,21
2022-02-14 2022-02-10 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
F - Taxes -1.057 893.650 -0,12 47,12 -49.806 42.108.788
2022-02-01 2022-01-28 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
F - Taxes -931 894.707 -0,10 38,59 -35.927 34.526.743
2022-01-25 2022-01-21 4 APLS Apellis Pharmaceuticals, Inc.
Stock Option (Right to Buy)
A - Award 36.951 36.951
2022-01-25 2022-01-21 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
A - Award 26.051 895.638 3,00
2021-06-25 2021-06-24 4 APLS Apellis Pharmaceuticals, Inc.
Stock Option (Right to Buy)
M - Exercise X -6.250 368.999 -1,67
2021-06-25 2021-06-24 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale X -6.250 869.587 -0,71 65,61 -410.062 57.053.603
2021-06-25 2021-06-24 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
M - Exercise X 6.250 875.837 0,72 2,67 16.688 2.338.485
2021-05-25 2021-05-24 4 APLS Apellis Pharmaceuticals, Inc.
Stock Option (Right to Buy)
M - Exercise X -6.250 375.249 -1,64
2021-05-25 2021-05-24 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale X -6.250 869.587 -0,71 47,40 -296.250 41.218.424
2021-05-25 2021-05-24 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
M - Exercise X 6.250 875.837 0,72 2,67 16.688 2.338.485
2021-04-29 2021-04-28 4 APLS Apellis Pharmaceuticals, Inc.
Stock Option (Right to Buy)
M - Exercise -4.500 381.499 -1,17
2021-04-29 2021-04-28 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
M - Exercise 4.500 869.587 0,52 2,67 12.015 2.321.797
2021-04-26 2021-04-23 4 APLS Apellis Pharmaceuticals, Inc.
Stock Option (Right to Buy)
M - Exercise X -6.250 385.999 -1,59
2021-04-26 2021-04-23 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale X -6.250 865.087 -0,72 46,13 -288.312 39.906.463
2021-04-26 2021-04-23 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
M - Exercise X 6.250 871.337 0,72 2,67 16.688 2.326.470
2021-03-11 2021-03-10 4 APLS Apellis Pharmaceuticals, Inc.
Stock Option (Right to Buy)
M - Exercise -6.250 392.249 -1,57
2021-03-11 2021-03-10 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale -6.250 865.087 -0,72 50,74 -317.125 43.894.514
2021-03-11 2021-03-10 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
M - Exercise 6.250 871.337 0,72 2,67 16.688 2.326.470
2021-02-11 2021-02-10 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
F - Taxes -688 865.087 -0,08 47,72 -32.831 41.281.952
2021-02-01 2021-01-28 4 APLS Apellis Pharmaceuticals, Inc.
Stock Option (Right to Buy)
A - Award 11.250 11.250
2021-02-01 2021-01-28 4 APLS Apellis Pharmaceuticals, Inc.
Stock Option (Right to Buy)
A - Award 45.000 45.000
2021-02-01 2021-01-28 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
A - Award 1.875 865.775 0,22
2021-02-01 2021-01-28 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
A - Award 7.500 863.900 0,88
2020-03-12 2020-03-10 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
G - Gift -161.656 847.025 -16,03
2020-02-14 2020-02-13 4 APLS Apellis Pharmaceuticals, Inc.
Stock Option (Right to Buy)
M - Exercise X -117.205 0 -100,00
2020-02-14 2020-02-13 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale -55.398 1.008.681 -5,21 40,98 -2.270.155 41.334.739
2020-02-14 2020-02-13 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
M - Exercise 117.205 1.064.079 12,38 2,14 250.819 2.277.129
2020-02-14 2020-02-12 4 APLS Apellis Pharmaceuticals, Inc.
Stock Option (Right to Buy)
M - Exercise X -117.206 117.205 -50,00
2020-02-14 2020-02-12 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale -52.075 946.874 -5,21 42,80 -2.228.966 40.529.048
2020-02-14 2020-02-12 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
M - Exercise 117.206 998.949 13,29 2,14 250.821 2.137.751
2020-02-12 2020-02-10 4 APLS Apellis Pharmaceuticals, Inc.
Stock option (right to buy)
A - Award 56.250 56.250
2020-02-12 2020-02-10 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
A - Award 9.375 891.118 1,06
2019-09-26 2019-09-25 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale X -1.010 881.743 -0,11 25,64 -25.897 22.608.772
2019-09-26 2019-09-25 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale X -20.531 882.753 -2,27 25,24 -518.161 22.278.920
2019-09-25 2019-09-24 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale X -1.295 903.284 -0,14 24,96 -32.321 22.544.162
2019-09-25 2019-09-24 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale X -20.307 904.579 -2,20 24,56 -498.760 22.217.365
2019-09-25 2019-09-23 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale X -100 924.886 -0,01 25,53 -2.553 23.612.340
2019-09-25 2019-09-23 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale X -20.758 924.986 -2,19 25,07 -520.362 23.187.549
2019-02-12 2019-02-08 4 APLS Apellis Pharmaceuticals, Inc.
Stock option (right to buy)
A - Award 95.000 95.000
2018-05-09 2018-05-07 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
J - Other 384.292 945.744 68,45
2018-02-21 2018-02-16 4 APLS Apellis Pharmaceuticals, Inc.
Stock Option (right to buy)
A - Award 110.000 110.000
2017-11-08 3 APLS Apellis Pharmaceuticals, Inc.
Common Stock
1.122.904
2017-11-08 3 APLS Apellis Pharmaceuticals, Inc.
Common Stock
1.122.904
P
Åbent marked eller privat køb af ikke-afledte eller afledte værdipapirer
S
Åbent marked eller privat salg af ikke-afledte eller afledte værdipapirer
A
Tildeling, tildeling eller anden erhvervelse af værdipapirer fra virksomheden (såsom en option)
C
Konvertering af derivat
D
Salg eller overførsel af værdipapirer tilbage til virksomheden
F
Betaling af udnyttelseskurs eller skatteforpligtelse ved brug af en del af værdipapirer modtaget fra selskabet
G
Gave af værdipapirer af eller til insideren
K
Aktieswaps og lignende sikringstransaktioner
M
Udnyttelse eller konvertering af afledt værdipapir modtaget fra virksomheden (såsom en option)
V
En transaktion rapporteret frivilligt på formular 4
J
Andet (ledsaget af en fodnote, der beskriver transaktionen)